Company intelligence / Profile preview
F-star
Cambridge, England, United Kingdom
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
F-star’s tetravalent bispecific antibody programs have shown promising safety and preliminary clinical efficacy in Phase 2 trials for PD-1 resistant and naive settings in solid tumors (including head and neck cancer, NSCLC, DLBCL). The bispecific platform is designed for improved immune system activation and tumor targeting; multiple programs are progressing through mid-stage clinical trials
- Therapeutic areas
- Oncology
- Modalities
- Bispecific monoclonal antibodyMonoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on F-star.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F-star.